20-F/A: Adlai Nortye Amends 2024 Annual Report, Updates Auditor Information

Adlai Nortye files an amendment to its 2024 annual report to reflect changes in its independent registered public accounting firm and revisions to previously issued financial statements.

Summary

• Adlai Nortye Ltd. has amended its annual report on Form 20-F for the year ended December 31, 2024.
• The amendment addresses changes related to the company's independent registered public accounting firm.
• The company has filed an audit report from its former auditor for the years ended December 31, 2023.
• Certain wording in notes to the audited consolidated financial statements has been adjusted.
• Consent letters from both the current and former auditors have been filed.
• The company revised its previously issued audited consolidated financial statements as of and for the year ended December 31, 2023 and unaudited consolidated interim financial statements as of and for the six months ended June 30, 2024 to correct the accounting treatment for the sale of an exclusive option to enter into a license agreement.
• The revision reflects a US$5.0 million reduction to the Companys revenue and a US$0.6 million reduction to the Companys income tax expense for the year ended December 31, 2023.
• The Companys contract liability will be revised to increase by US$5.0 million, the accumulated deficit will increase by US$4.4 million, and other payables and accruals will decrease by US$0.6 million as of December 31, 2023 and as of June 30, 2024, respectively.
• The company has identified material weaknesses in its internal control over financial reporting and is implementing a remediation plan.

Sentiment

Score: 5

Explanation: The document contains both positive (remediation efforts) and negative (material weakness, restatement) elements, resulting in a neutral sentiment score.

Positives

• The company is taking steps to remediate the identified material weakness in internal control over financial reporting.
• The company has filed consent letters from both its current and former auditors.

Negatives

• The company identified and revised its previously issued audited consolidated financial statements as of and for the year ended December 31, 2023 and unaudited consolidated interim financial statements as of and for the six months ended June 30, 2024 to correct the accounting treatment for the sale of an exclusive option to enter into a license agreement.
• A material weakness exists in the company's internal control over financial reporting.

Risks

• Failure to remediate the material weakness in internal control over financial reporting could lead to inaccurate financial reporting and a decline in investor confidence.
• The delisting of the ADSs, or the threat of such delisting, may materially and adversely affect the value of your investment.
• The PRC government may intervene or influence our operations at any time, or may exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our securities.

Future Outlook

The document does not reflect events occurring after the filing of the Annual Report and does not modify or update the disclosure therein in any way except as described above.

Industry Context

The announcement reflects standard regulatory compliance procedures for publicly listed companies, particularly those with international operations and exposure to evolving accounting standards and regulatory oversight.

Comparison to Industry Standards

• The revision of financial statements due to accounting errors is not uncommon in the pharmaceutical industry.
• Companies like Novartis and Eisai, which have licensing agreements with Adlai Nortye, are also subject to similar accounting and regulatory standards.
• The identification and remediation of material weaknesses in internal control over financial reporting is a common challenge for emerging growth companies in the biopharmaceutical sector.
• Comparable companies such as BeiGene, Hutchison China MediTech, and Zai Lab also face similar regulatory and compliance requirements as companies with substantial operations in China listed on U.S. exchanges.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the restatement and disclosure of material weaknesses.
• The company's ability to attract future investment may be affected by the identified material weakness.
• The company's reputation may be affected by the restatement and disclosure of material weaknesses.

Next Steps

• Continue implementing the remediation plan to address the material weakness in internal control over financial reporting.
• Monitor and comply with evolving PRC laws and regulations.
• Prepare for potential future audits by the PCAOB.

Key Dates

Keywords

annual report, auditor, financial statements, material weakness, internal control, Adlai Nortye